Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lowell Brian Anthony"'
Autor:
Aman Chauhan, Susan M. Christner, Jan Hendrik Beumer, Charles Kunos, Aman Khurana, Riham El Khouli, Heidi Weiss, Donglin Yan, Heloisa P. Soares, Thorvardur Ragnar Halfdanarson, Daneng Li, William Edgar Carson, Mark B Evers, Percy Ivy, Elise C. Kohn, Larry Rubinstein, Susanne M. Arnold, Jill Kolesar, Lowell Brian Anthony, Bhavana Konda
Publikováno v:
Journal of Clinical Oncology. 41:648-648
648 Background: Radiation is a potent inducer of DNA double-strand breaks, and ribonucleotide reductase (RNR) is the rate-limiting enzyme for conversion of ribonucleoside diphosphate to deoxyribonucleotide diphosphate, and thus repair of DNA in this
Autor:
Aman Chauhan, Jill Kolesar, Donglin Yan, Daneng Li, Aman Khurana, William Edgar Carson, Susanne M. Arnold, Steven Gore, Larry Rubinstein, Elise C. Kohn, Percy Ivy, Ying Xiao, Yuni Dewaraja, Heloisa P. Soares, Jan Hendrik Beumer, Bhavana Konda, Vineeth Sukrithan, Lowell Brian Anthony
Publikováno v:
Journal of Clinical Oncology. 41:TPS658-TPS658
TPS658 Background: Radiolabeled somatostatin analogues provide a means of delivering targeted radiation with a high therapeutic index to NETs that express somatostatin receptors (SSTRs). Radiolabeled somatostatin analogue Lutetium 177 DOTATATE (Lutat
Autor:
Aman Chauhan, Charles Kunos, Donglin Yan, Aman Khurana, Riham Khouli, Michael J. Cavnar, Prakash Pandalai, Joseph Kim, Lowell Brian Anthony
Publikováno v:
Journal of Clinical Oncology. 40:TPS516-TPS516
TPS516 Background: PRRT using Lutetium Lu 177 Dotatate, has been approved by the FDA for metastatic, progressive gastroenteropancreatic neuroendocrine tumors (GEPNETs). Despite an impressive progression-free survival noted in NETTER-1 study, most pat
Autor:
Aman Chauhan, Alexandre Prieur, Jill Kolesar, Susanne Arnold, Thierry Cousin, Lea Francoise Payen, Madison Sands, Dana Napier, Mark Evers, Lowell Brian Anthony
Publikováno v:
Journal of Clinical Oncology. 38:628-628
628 Background: Neuroendocrine neoplasms (NENs) are heterogeneous tumors which originate from various organs and are of variable aggressiveness based on grade and morphology. Current biomarkers for NENs lack sensitivity and specificity, especially fo
Publikováno v:
Journal of Clinical Oncology. 36:e22217-e22217
Autor:
Stacie Hudgens, Jonathon Gable, Matthew H. Kulke, Emily Bergsland, Lowell Brian Anthony, Martyn E. Caplin, Kjell E. Oberg, Marianne Pavel, Phillip Banks, Qi Melissa Yang, Pablo Lapuerta
Publikováno v:
Journal of Clinical Oncology. 35:e15132-e15132
e15132 Background: Telotristat ethyl is a tryptophan hydroxylase inhibitor in development for the treatment of carcinoid syndrome (CS) in patients who receive somatostatin analog (SSA) therapy. In TELESTAR, a pivotal Phase 3 study, telotristat ethyl